Imatinib treatment attenuates growth and inflammation of angiotensin II induced abdominal aortic aneurysm

Show full item record



Permalink

http://hdl.handle.net/10138/224038

Citation

Vorkapic , E , Dugic , E , Vikingsson , S , Roy , J , Mäyränpää , M , Eriksson , P & Wagsater , D 2016 , ' Imatinib treatment attenuates growth and inflammation of angiotensin II induced abdominal aortic aneurysm ' , Atherosclerosis , vol. 249 , pp. 101-109 . https://doi.org/10.1016/j.atherosclerosis.2016.04.006

Title: Imatinib treatment attenuates growth and inflammation of angiotensin II induced abdominal aortic aneurysm
Author: Vorkapic, Emina; Dugic, Elma; Vikingsson, Svante; Roy, Joy; Mäyränpää, Mikko; Eriksson, Per; Wagsater, Dick
Contributor: University of Helsinki, Medicum
Date: 2016-06
Language: eng
Number of pages: 9
Belongs to series: Atherosclerosis
ISSN: 0021-9150
URI: http://hdl.handle.net/10138/224038
Abstract: Background: Abdominal aortic aneurysm (AAA) is characterized by vascular remodeling with increased infiltration of inflammatory cells and apoptosis/modulation of vascular smooth muscle cells (SMCs). Imatinib is a selective inhibitor of several tyrosine kinases, including PDGF receptors, Abl, and c-kit. The objective of this study was to characterize the potential protective role of imatinib on AAA development and the molecular mechanisms involved. Methods: Male ApoE(-/)-mice were infused with angiotensin (Ang) II (1000 ng/kg/min) for 4 weeks to induce AAA or saline as controls. Daily treatment with 10 mg/kg imatinib, or tap water as control, was provided via gavage for 4 weeks. Results: Treatment with imatinib was found to decrease the aortic diameter and vessel wall thickness, mediated by multiple effects. Imatinib treatment in AngII infused mice resulted in a reduced cellular infiltration of CD3 epsilon positive T lymphocytes by 86% and reduced gene expression of mast cell chymase by 50% compared with AngII infused mice lacking imatinib. Gene expression analysis of SMC marker SM22a demonstrated an increase by 48% together with a more intact medial layer after treatment with imatinib as evaluated with SM22 alpha immunostaining. Conclusion: Present findings highlight the importance of tyrosine kinase pathways in the development of AAA. Our results show, that imatinib treatment inhibits essential mast cell, T lymphocyte and SMC mediated processes in experimental AAA. Thus, our results support the idea that tyrosine kinase inhibitors may be useful in the treatment of pathological vascular inflammation and remodeling in conditions like AAA. (C) 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NCND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Subject: Abdominal aortic aneurysm
Vascular inflammation
Imatinib
Angiotensin II
MAST-CELLS
C-KIT
TYROSINE KINASE
PDGF-C
MESYLATE
MICE
ATHEROSCLEROSIS
PATHOGENESIS
EXPRESSION
INHIBITORS
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S002191501630137X_main.pdf 1.996Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record